Annual Meeting Proceedings, Part 2 |
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Common terms and phrases
adjuvant adv RCC adverse events AstraZeneca atamestane Background breast cancer Bristol-Myers Squibb Ca/D Cancer Center Cancer lnstitute capecitabine chemotherapy cisplatin Clinical Oncology commercial interest cycles cyclophosphamide D2+PAND disclosure disease Docetaxel drugs DTlC efficacy Eli Lilly enrolled Exemestane first-line fluorouracil gastric cancer Gastrointestinal Noncolorectal gemcitabine hazard ratio Hospital immediate family member—defined invasive breast cancer involving the sharing Journal of Clinical letrozole lFN a2b lFN-a lnc Pfizer ltaly matter under consideration median TTP member—defined as someone metastatic months mRCC mths neutropenia non-T adjRx Novartis Novartis AstraZeneca NSABP Oncology Oral Presentation overall survival oxaliplatin patients pts pCR rates Pfizer phase lll trial poor-risk primary endpoint prior adjuvant raloxifene randomized phase lll regimen relationship involving Results sanofi-aventis sharing of income significant differences Society of Clinical sunitinib tamoxifen TEMSR Tier toremifene toxicity treatment TRTFU University Wyeth Research
Bibliographic information
| Title | Annual Meeting Proceedings, Part 2 |
| Author | American Society of Clinical Oncology. Meeting |
| Contributor | American Society of Clinical Oncology |
| Publisher | American Society of Clinical Oncology, 2006 |
| Original from | University of Chicago |
| Digitized | May 13, 2011 |
| Export Citation | BiBTeX EndNote RefMan |